The Study To assess The Effectiveness Of Homoeopathic Medicine Viburnum Opulus In Cases Of Pelvic Inflammatory Disease In Comparison To Individualized Medicines.

Phase 3

Conditions: Health Condition 1: N739- Female pelvic inflammatory disease, unspecified

Registration Number: CTRI/2022/06/043100

Lead Sponsor: Dr MPK Homoeopathic Medical College Hospital and Research Centre

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1. Previously diagnosed cases of PID seeking homoeopathic treatment or newly diagnosed.

2. As per sign & symptoms and CDC (adopted from DC Duttaâ??s textbook of gynecology 7th edition) Patients with 3-4 confirmatory sign and symptoms given below shall be enrolled for the study irrespective of the diagnosis based on investigations-

a. Pelvic pain or lower abdomen pain or back pain.

b. Abnormal & heavy Vaginal discharge (purulent and or copious)

c. Offensive vaginal odor.

d. Cervical motion tenderness.

e. Lower abdomen tenderness.

f. Adnexal tenderness.

g. Pruritis vulva.

h. Burning.

i. Dyspareunia.

j. Irregular vaginal bleeding.

k. Fever

Diagnostic criteria-

1.symptoms as mentioned above.

2.USG/ laboratory investigation done if required in case of unclear symptoms given above.

Exclusion Criteria

1. Cases which required any emergency treatment.

2. Patient pursuing other treatment and were not willing to leave it.

3. Pregnant women and lactating mothers will not be included in the study.

4.Immunocompromised patient such as suffering from HIV, Hepatitis B/C etc.

5.Cases with multi systemic illness will be excluded from the study and cases with advance pathology & malignancy.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in VAS score will be noted for every symptom before, during and after treatment and shall be analysed to assess the efficacy of treatment given.Timepoint: Changes in VAS score will be noted for every symptom before, during and after treatment and shall be analysed to assess the efficacy of treatment given at 12 month.

Secondary Outcome Measures

Name	Time	Method
Changes in WHO QOL-BREF scale will be noted for before and after treatment and shall be analysed to assess the efficacy of treatment given .Timepoint: 1year